Literature DB >> 22720863

Usefulness of sennoside as an agent for mechanical bowel preparation prior to elective colon cancer surgery.

Keiichiro Ishibashi1, Kensuke Kumamoto, Kouki Kuwabara, Naoko Hokama, Toru Ishiguro, Tomonori Ohsawa, Norimichi Okada, Tatsuya Miyazaki, Masaru Yokoyama, Yoshitaka Tsuji, Norihiro Haga, Hideyuki Ishida.   

Abstract

OBJECTIVE: We retrospectively evaluated the usefulness of sennoside as an agent for mechanical bowel preparation prior to elective colon cancer surgery.
METHODS: A total of 86 patients were given 12 mg of sennoside on the evening prior to resective surgery for colon cancer, followed by intravenous antimicrobial prophylaxis used on the day of surgery or until postoperative day 2.
RESULTS: The incidence of surgical site infection in the study group was 4.7%, which was comparable to that in the historical control patients (3.5%, p>0.99), who had received polyethylene glycol for mechanical bowel preparation prior to colon surgery. On multivariate logistic regression analysis, only body mass index (p=0.04) was an independent significant factor affecting the surgical site infection. The intraoperative spillage was not influenced by the presence of stenosis, although the amount of fecal matter was higher in the upstream colon segment (p<0.01) and downstream segment (p=0.07) in patients with a stenotic lesion occupying more than two-thirds of the lumen (n=29) than in those without such severe stenosis (n=57).
CONCLUSION: Sennoside seems to be an acceptable agent for mechanical bowel preparation even in patients with stenosis.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22720863     DOI: 10.1016/j.asjsur.2012.04.022

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  3 in total

1.  Comparison of the risk of surgical site infection and feasibility of surgery between sennoside versus polyethylene glycol as a mechanical bowel preparation of elective colon cancer surgery: a randomized controlled trial.

Authors:  Yusuke Tajima; Hideyuki Ishida; Azusa Yamamoto; Noriyasu Chika; Hisashi Onozawa; Takeaki Matsuzawa; Kensuke Kumamoto; Keiichiro Ishibashi; Erito Mochiki
Journal:  Surg Today       Date:  2015-08-30       Impact factor: 2.549

2.  A New Model of Diarrhea with Spleen-Kidney Yang Deficiency Syndrome.

Authors:  Jiajie Zhu; Shan Liu; Yu Guo; Liwei Hou; Xiaolan Su; Yijie Li; Boyu Han; Dengke Liu; Qingguo Wang; Jiande Jd Chen; Wei Wei
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-30       Impact factor: 2.629

3.  Ellagic acid and Sennoside B inhibit osteosarcoma cell migration, invasion and growth by repressing the expression of c-Jun.

Authors:  Wei Xu; Jinjin Xu; Ting Wang; Weibo Liu; Haifeng Wei; Xinghai Yang; Wangjun Yan; Wang Zhou; Jianru Xiao
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.